Edwards Lifesciences Corp (EW) continues to display strong performance with robust revenue growth, beating Q3 2025 earnings expectations. Various investment firms and institutional investors are altering their positions in the company. Primecap Management Co. CA, Vanguard Group Inc., Citigroup Inc., and Creative Planning are among those expanding their holdings. However, others such as SG Americas Securities LLC, Intech Investment Management LLC, Thoroughbred Financial Services LLC, and Bank of New York Mellon Corp have sold shares. Edwards has updated ESC/EACTS Guidelines for Severe Aortic Stenosis, a factor likely driving its strong performance. The Bull Case Theory suggests continuing growth. Potential investors are recommended to consider buying Edwards Lifesciences stock, as strong financials guide market performance. On a cautious note, EW shares may experience increased volatility due to earnings upgrades and changes. The corporation also announced a CFO Transition Plan, which adds to market speculation.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 22 Nov 2025 12:11:08 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -4
